Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
Add more filters

Publication year range
1.
N Engl J Med ; 390(6): 522-529, 2024 Feb 08.
Article in English | MEDLINE | ID: mdl-38324485

ABSTRACT

A multinational outbreak of nosocomial fusarium meningitis occurred among immunocompetent patients who had undergone surgery with epidural anesthesia in Mexico. The pathogen involved had a high predilection for the brain stem and vertebrobasilar arterial system and was associated with high mortality from vessel injury. Effective treatment options remain limited; in vitro susceptibility testing of the organism suggested that it is resistant to all currently approved antifungal medications in the United States. To highlight the severe complications associated with fusarium infection acquired in this manner, we report data, clinical courses, and outcomes from 13 patients in the outbreak who presented with symptoms after a median delay of 39 days.


Subject(s)
Disease Outbreaks , Fusariosis , Fusarium , Iatrogenic Disease , Meningitis, Fungal , Humans , Antifungal Agents/therapeutic use , Fusariosis/epidemiology , Fusariosis/etiology , Fusarium/isolation & purification , Iatrogenic Disease/epidemiology , Meningitis, Fungal/epidemiology , Meningitis, Fungal/etiology , Mexico/epidemiology , Disease Outbreaks/statistics & numerical data , Internationality , Immunocompetence , Drug Resistance, Fungal , Analgesia, Epidural/adverse effects
2.
Mycoses ; 66(3): 211-218, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36349480

ABSTRACT

BACKGROUND: Invasive fusariosis mainly affects immunocompromised patients including haematopoietic stem cell transplant recipients and those with haematologic malignancy. There are limited studies on invasive fusariosis in the Asia-Pacific region. OBJECTIVE: To describe the clinical characteristics and outcomes of invasive and non-invasive fusariosis in South Korea. PATIENTS/METHODS: From 2005 to 2020, patients with fusariosis who met the revised European Organisation for Research and Treatment of Cancer and the Mycoses Study Group criteria for the definition of proven or probable invasive fusariosis, and those with non-invasive fusariosis were retrospectively reviewed in a tertiary medical centre in Seoul, South Korea. RESULTS: Overall, 26 and 75 patients had invasive and non-invasive fusariosis, respectively. Patients with invasive fusariosis commonly had haematologic malignancy (62%), were solid organ transplant recipients (23%), and had a history of immunosuppressant usage (81%). In non-invasive fusariosis, diabetes mellitus (27%) and solid cancer (20%) were common underlying conditions. Disseminated fusariosis (54%) and invasive pulmonary disease (23%) were the most common clinical manifestations of invasive fusariosis; skin infection (48%) and keratitis (27%) were the most common manifestations of non-invasive fusariosis. Twenty-eight-day and in-hospital mortalities were high in invasive fusariosis (40% and 52%, respectively). In multivariate analysis, invasive fusariosis (adjusted odds ratio, 9.6; 95% confidence interval 1.3-70.8; p = .03) was an independent risk factor for 28-day mortality. CONCLUSIONS: Patients with invasive fusariosis were frequently immunocompromised, and more than half had disseminated fusariosis. Invasive fusariosis was associated with poor prognosis.


Subject(s)
Fusariosis , Fusarium , Hematologic Neoplasms , Humans , Fusariosis/drug therapy , Fusariosis/epidemiology , Fusariosis/etiology , Antifungal Agents/therapeutic use , Retrospective Studies , Hematologic Neoplasms/complications , Hematologic Neoplasms/drug therapy , Immunocompromised Host , Republic of Korea/epidemiology
3.
Pediatr Dermatol ; 40(3): 503-506, 2023.
Article in English | MEDLINE | ID: mdl-36334032

ABSTRACT

Fusarium is a polyphyletic genus of plant pathogens, members of which can cause opportunistic human infections with varying superficial and systemic presentations, including disseminated infections which typically occur in immunocompromised patients and have a poor prognosis. Treatment is challenging due to intrinsic resistance to many antifungal agents, and antifungal susceptibility testing is therefore essential. Early suspicion, isolation of the organism, and prompt initiation of management are crucial to improving survival. We present a case of disseminated Bisifusarium infection following toxic epidermal necrolysis in a child with B-cell acute lymphoblastic leukemia, successfully treated with liposomal amphotericin B, voriconazole, flucytosine, and terbinafine.


Subject(s)
Fusariosis , Fusarium , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma , Stevens-Johnson Syndrome , Humans , Child , Fusariosis/diagnosis , Fusariosis/drug therapy , Fusariosis/etiology , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/etiology , Antifungal Agents/therapeutic use , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Immunocompromised Host
4.
Mycoses ; 63(8): 787-793, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32458510

ABSTRACT

BACKGROUND: Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non-Aspergillus invasive mould infections (NAIMIs) in this setting, OBJECTIVES: To review our recent experience and the published literature on the topic. PATIENTS/METHODS: We present a case of invasive sinusitis caused by Fusarium in a patient with refractory chronic lymphocytic leukaemia (CLL) who was treated with IBR and review the 12 published cases of NAIMIs during IBR. RESULTS: Nearly all cases of NAIMIs in the setting of IBR use were encountered in patients with CLL. Mixed fungal infections, brain involvement and late-onset infections were common. CONCLUSIONS: Although rare, NAIMIs should be considered in patients who receive IBR.


Subject(s)
Adenine/analogs & derivatives , Aspergillosis , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Mycoses/etiology , Piperidines/adverse effects , Adenine/adverse effects , Aged , Anticarcinogenic Agents/adverse effects , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/etiology , Aspergillus/isolation & purification , Aspergillus/pathogenicity , Female , Fungi/isolation & purification , Fungi/pathogenicity , Fusariosis/drug therapy , Fusariosis/etiology , Fusarium/isolation & purification , Fusarium/pathogenicity , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Mucorales/isolation & purification , Mucorales/pathogenicity
6.
Appl Microbiol Biotechnol ; 102(24): 10353-10359, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30315352

ABSTRACT

The in vitro susceptibility of gentamicin fractions against Fusarium growth was the subject of this retrospective study. Fusariosis was earlier an exceptionally rare human disease and an unrealistic idea to treat soil saprophytes and plant pathogens with expensive antibiotics such as gentamicins or their minor components. Disseminated fusariosis is now the second most frequent lethal fungal infection after aspergillosis especially in neutropenic patients with hematologic malignancy. Results of this study obtained between May and November 1973 were interesting but not practicable and remained unpublished. Seven Fusarium and 28 other fungal strains were tested for their susceptibility to gentamicin B1. The anti-Fusarium activity of gentamicin B1 was between 0.2 and 3.1 µg/ml minimum inhibitory concentration (MIC) values. The MIC values of clotrimazol and amphotericin B against Fusarium species were significantly higher, 3.1-12.5 µg/ml and 3.1-50 µg/ml, respectively. Gentamicin B1 and its structurally related congeners including hygromycin B, paromomycin, tobramycin (nebramycin factor 5'), nebramycin (nebramycin factor 4), and sisomicin exerted strong in vitro inhibition against Fusarium species between 0.2 and 12.5 µg/ml concentrations. The antibacterial MIC concentration of gentamicin B1 tested on 20 bacterial strains ranged between 0.1 and 50 µg/ml. Gentamicin B1, a minor fraction of the gentamicin complex, inhibited effectively the growth of Gram-positive (Staphylococcus, Streptococcus, Bacillus subtilis) bacteria and Gram-negative (Escherichia coli, Salmonella, Proteus, Pseudomonas) pathogens. Gentamicins and related aminoglycoside antibiotics are used in medical practice. It is proposed that due to the increasing incidence of fusariosis and drug resistance, gentamicin components, particularly minor fraction B1 and related aminoglycoside antibiotics, could be tested for their in vivo activity against fusariosis and aspergillosis either alone or in combination with other antifungal agents.


Subject(s)
Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Fusarium/drug effects , Gentamicins/pharmacology , Administration, Topical , Anti-Bacterial Agents/pharmacology , Aspergillosis/etiology , Fusariosis/drug therapy , Fusariosis/etiology , Humans , Microbial Sensitivity Tests , Structure-Activity Relationship
7.
Acta Neurol Taiwan ; 26(3): 128-132, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-29468621

ABSTRACT

PURPOSE: Invasive mycosis caused by the Aspergillus, Fusarium, and Mucor can be fetal, especially in the immunocompromised patients with central nervous system (CNS) involvement. Here we present a case of CNS Fusarium infection, and this is the first reported case of Fusarium brain abscess in Taiwan. CASE REPORT: A 65-year-old woman presented with fever and conscious disturbance for 3 days. Neurological examination showed stupor consciousness, neck stiffness, multiple cranial nerves palsy, and bilateral Babinski signs. Magnetic resonance imaging showed multifocal lesions involving medulla oblongata, pons, bilateral cerebral peduncles, and bilateral cerebellar peduncles. Cerebrospinal fluid (CSF) study revealed neutrophil predominant pleocytosis, but both blood and CSF culture were negative. We treated patient with ceftriaxone and vancomycin initially as empiric therapy for suspected bacterial meningoencephalitis. However, chronic sinusitis with fungal ball and brain abscess were later found. Despite antifungal treatment and surgical intervention, patient expired 3 months after admission. Fungal culture of the brain abscess disclosed Fusarium species 2 weeks after her death. CONCLUSION: CNS Fusarium infection should be considered when an immunocompromised patient presenting with fever, conscious change, cranial nerve palsies, and angioinvasion suggested by brain imaging. To properly manage the disease, early effective antifungal therapy and neurosurgical intervention are important.


Subject(s)
Brain Abscess/etiology , Diabetes Complications/etiology , Fusariosis/etiology , Liver Cirrhosis/complications , Aged , Antifungal Agents/therapeutic use , Brain Abscess/drug therapy , Brain Abscess/pathology , Female , Fusariosis/drug therapy , Fusariosis/pathology , Humans
8.
Actas Dermosifiliogr ; 108(6): e45-e48, 2017.
Article in English, Spanish | MEDLINE | ID: mdl-28411862

ABSTRACT

Photodynamic therapy (PDT) is a therapeutic modality with significant antimicrobial activity. We present 2 cases of chronic lower limb ulcers in which fungal and bacterial superinfection complicated management. PDT with methylene blue as the photosensitizer led to clinical and microbiological cure with no significant adverse effects. PDT with methylene blue is a valid option for the management of superinfected chronic ulcers, reducing the use of antibiotics and the induction of resistance.


Subject(s)
Fusariosis/drug therapy , Fusarium/drug effects , Leg Ulcer/microbiology , Methylene Blue/therapeutic use , Mycoses/drug therapy , Photochemotherapy , Photosensitizing Agents/therapeutic use , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Superinfection/drug therapy , Adult , Aged , Burns, Electric/complications , Burns, Electric/microbiology , Chronic Disease , Female , Fusariosis/etiology , Humans , Immunocompromised Host , Intraoperative Complications , Leg Ulcer/complications , Mycoses/etiology , Pseudomonas Infections/etiology , Superinfection/etiology , Wound Healing , Wound Infection/drug therapy , Wound Infection/microbiology
9.
Appl Environ Microbiol ; 82(21): 6483-6489, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27663024

ABSTRACT

Fusarium oxysporum is typically a soilborne fungus but can also be found in aquatic environments. In hospitals, water distribution systems may be reservoirs for the fungi responsible for nosocomial infections. F. oxysporum was previously detected in the water distribution systems of five French hospitals. Sixty-eight isolates from water representative of all hospital units that were previously sampled and characterized by translation elongation factor 1α sequence typing were subjected to microsatellite analysis and full-length ribosomal intergenic spacer (IGS) sequence typing. All but three isolates shared common microsatellite loci and a common two-locus sequence type (ST). This ST has an international geographical distribution in both the water networks of hospitals and among clinical isolates. The ST dominant in water was not detected among 300 isolates of F. oxysporum that originated from surrounding soils. Further characterization of 15 isolates by vegetative compatibility testing allowed us to conclude that a clonal lineage of F. oxysporum circulates in the tap water of the different hospitals. IMPORTANCE: We demonstrated that a clonal lineage of Fusarium oxysporum inhabits the water distribution systems of several French hospitals. This clonal lineage, which appears to be particularly adapted to water networks, represents a potential risk for human infection and raises questions about its worldwide distribution.


Subject(s)
Drinking Water/microbiology , Fusarium/genetics , Fusarium/isolation & purification , Hospitals , DNA, Fungal/isolation & purification , DNA, Intergenic , France/epidemiology , Fusariosis/epidemiology , Fusariosis/etiology , Fusariosis/microbiology , Fusarium/classification , Humans , Microsatellite Repeats , Peptide Elongation Factor 1/genetics , Phylogeny , Sequence Analysis, DNA
10.
Clin Infect Dis ; 60(6): 875-80, 2015 Mar 15.
Article in English | MEDLINE | ID: mdl-25425628

ABSTRACT

BACKGROUND: Risk factors for invasive fusariosis (IF) have not been characterized. We attempted to identify risk factors for IF in a prospective cohort of hematologic patients treated in 8 centers in Brazil. METHODS: Patients with (cases) and without (controls) proven or probable IF diagnosed in a cohort of patients with acute myeloid leukemia (AML) or myelodysplasia (MDS), and in allogeneic hematopoietic cell transplant (HCT) recipients (early, until day 40; late, after day 40 posttransplant) were compared by univariate Cox regression analysis. RESULTS: Among 237 induction remission courses of AML/MDS and 663 HCTs (345 allogeneic and 318 autologous), 25 cases of IF were diagnosed. In the AML/MDS cohort, active smoking (hazard ratio [HR], 9.11 [95% confidence interval {CI}, 2.04-40.71]) was associated with IF. Variables associated with IF in the early phase of allogeneic HCT were receipt of antithymocyte globulin (HR, 22.77 [95% CI, 4.85-101.34]), hyperglycemia (HR, 5.17 [95% CI, 1.40-19.11]), center 7 (HR, 5.15 [95% CI, 1.66-15.97]), and AML (HR, 4.38 [95% CI, 1.39-13.81]), and in the late phase were nonmyeloablative conditioning regimen (HR, 35.08 [95% CI, 3.90-315.27]), grade III/IV graft-vs-host disease (HR, 16.50 [95% CI, 2.67-102.28]), and previous invasive mold disease (HR, 10.65 [95% CI, 1.19-95.39]). CONCLUSIONS: Attempts to reduce the risk of IF may include smoking cessation, aggressive control of hyperglycemia, and the use of a mold-active agent as prophylaxis in patients receiving nonmyeloablative HCT or ATG in the conditioning regimen. Future research should further explore smoking and other prehospital variables as risks for IF.


Subject(s)
Fusariosis/etiology , Hematopoietic Stem Cell Transplantation , Leukemia, Myeloid, Acute/complications , Transplant Recipients , Adolescent , Adult , Aged , Aged, 80 and over , Antilymphocyte Serum/therapeutic use , Brazil , Child , Child, Preschool , Cohort Studies , Female , Fusariosis/diagnosis , Graft vs Host Disease , Humans , Infant , Infant, Newborn , Male , Middle Aged , Myelodysplastic Syndromes/complications , Prospective Studies , Remission Induction , Risk Factors , Smoking , Transplantation Conditioning , Young Adult
11.
Transpl Infect Dis ; 17(2): 259-66, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25648194

ABSTRACT

BACKGROUND: Recipients of lung transplantation (LT) and heart-lung transplantation (HLT) are at increased risk of infection, including invasive mold infections (IMIs). The clinical presentation, radiographic correlates, and outcomes of Aspergillus and non-AspergillusIMIs in this population have not been well documented. METHODS: LT and HLT recipients diagnosed with IMIs between 1990 and 2012 were identified using the Stanford Translational Research Integrated Database Environment and Stanford LT and HLT clinical database. Recipient clinical and radiographic characteristics were obtained via retrospective review of medical records and compared between Aspergillus and non-Aspergillus mold recipients. Risk factors for mortality were identified using multivariate logistic regression analysis. RESULTS: During the study period, 87 (14%) transplant recipients were diagnosed with IMIs. Aspergillus species were isolated in 63 (72%) and non-Aspergillus molds in 24 (28%) recipients. No significant difference was seen in presenting symptoms or radiographic findings between Aspergillus and non-Aspergillus mold recipients. Median time to diagnosis was 363 days in the Aspergillus group and 419 days in the non-Aspergillus group, with dissemination occurring only within the non-Aspergillus group (12.5%). Overall 90-day and 1-year mortality following IMI was 24% and 44%. One-year mortality was increased in the non-Aspergillus group (39.5% vs. 60.5%, P = 0.03). CONCLUSIONS: There is significant overlap in risk factors, presentation, and radiographic patterns in IMI in LT or HLT recipients. Non-Aspergillus molds were more likely to present late, with disseminated disease, and portend increased 1-year mortality.


Subject(s)
Aspergillosis/epidemiology , Fusariosis/epidemiology , Graft Rejection/prevention & control , Heart-Lung Transplantation , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Lung Transplantation , Mucormycosis/epidemiology , Adult , Aspergillosis/etiology , Aspergillosis/immunology , Cohort Studies , Female , Fusariosis/etiology , Fusariosis/immunology , Humans , Logistic Models , Male , Middle Aged , Mucormycosis/etiology , Mucormycosis/immunology , Mycoses/epidemiology , Mycoses/etiology , Mycoses/immunology , Retrospective Studies , Risk Factors , Scedosporium
13.
Biomedica ; 43(Sp. 1): 41-56, 2023 08 31.
Article in English, Spanish | MEDLINE | ID: mdl-37721903

ABSTRACT

The fusariosis is an opportunistic mycosis caused by Fusarium spp. Its clinical presentation depends on the immunological status of the host, especially in patients with hematooncological diseases, whose manifestations vary from localized to invasive fungal infections. Skin or blood culture helps to guide combined antifungal treatment with amphotericin B and voriconazole. Here, we present 13 cases in a period of eleven years of patients with cancer who developed disseminated fusariosis and their outcomes, together with a review of the related literature. In this series of cases, mortality was 61.5 % (8/13), despite the use of the antifungal. Out of the 13 cases, 11 had hematological neoplasia and 2 solid neoplasia. The most determinant risk factor was profound neutropenia. Skin involvement and positive blood cultures in most cases allowed combined treatment prescription. Persistent febrile neutropenia associated with skin lesions, onychomycosis, nodules, or lung masses lead to suspicion of Fusarium spp. fungal invasive infection. The aim of this series of cases is to remind healthcare professionals that oncological patients with deep and persistent febrile neutropenia can develop fusariosis.


La fusariosis es una micosis oportunista producida por Fusarium spp. Su presentación clínica depende del estado inmunológico del huésped, especialmente, el de aquellos con enfermedades hematooncológicas, cuyas manifestaciones varían desde formas localizadas hasta infección fúngica invasora. El cultivo de piel o de sangre permite orientar el tratamiento antifúngico combinado con anfotericina B y voriconazol. Se presentan 13 casos de pacientes con cáncer en un periodo de once años que desarrollaron fusariosis diseminada; asimismo, se hizo con una revisión extensa de la literatura. En esta serie de casos, la mortalidad fue del 61,5 % (8/13), a pesar del uso del antifúngico. De los 13 pacientes, 11 tenían neoplasia hematológica y 2 neoplasia sólida. El factor de riesgo más importante fue la neutropenia profunda. El compromiso de la piel y los hemocultivos positivos facilitaron la prescripción del tratamiento combinado en la mayoría de los casos. La neutropenia febril persistente asociada a lesiones cutáneas, la onicomicosis, los nódulos o las masas pulmonares permitieron sospechar una infección fúngica invasora por Fusarium spp. El objetivo de la presentación de esta serie de casos es recordar el diagnóstico de fusariosis a la comunidad médica en contacto con pacientes oncológicos, con neutropenia febril profunda y persistentes.


Subject(s)
Febrile Neutropenia , Fusariosis , Neoplasms , Humans , Fusariosis/drug therapy , Fusariosis/etiology , Antifungal Agents/therapeutic use , Research , Neoplasms/complications
15.
MMWR Morb Mortal Wkly Rep ; 61(17): 310-1, 2012 May 04.
Article in English | MEDLINE | ID: mdl-22552209

ABSTRACT

On March 5, 2012, the California Department of Public Health was notified of nine cases of clinically diagnosed fungal endophthalmitis at a single California ambulatory surgical center. The initial investigation, led by the Los Angeles County Department of Public Health, determined that in all cases patients had undergone vitrectomy with epiretinal membrane peeling using a dye called Brilliant Blue-G (BBG) from Franck's Compounding Lab, Ocala, Florida. This investigation has since expanded to involve intravitreal injection of triamcinolone-containing products from Franck's, an overall total of 33 cases in seven states, and collaboration between state and local health departments, CDC, and the Food and Drug Administration (FDA). This report describes the current investigative findings. Clinicians should be aware of the ongoing investigation and should avoid use of compounded products labeled as sterile from Franck's during this ongoing investigation.


Subject(s)
Disease Outbreaks , Drug Contamination , Endophthalmitis/epidemiology , Fusariosis/epidemiology , Indicators and Reagents/adverse effects , Ophthalmologic Surgical Procedures/adverse effects , Rosaniline Dyes/adverse effects , Ascomycota/isolation & purification , Drug Compounding , Drug Labeling , Endophthalmitis/etiology , Fusariosis/etiology , Fusarium/isolation & purification , Humans , Indicators and Reagents/chemistry , Pharmacies , Rosaniline Dyes/chemistry , United States/epidemiology , Vitrectomy/adverse effects
16.
Harefuah ; 151(8): 455-7, 499, 498, 2012 Aug.
Article in Hebrew | MEDLINE | ID: mdl-23350288

ABSTRACT

Invasive fungal infections are a major cause of morbidity and mortality in hematopoietic stem cell transplantation patients. In recent years, new resistant fungal strains have emerged, requiring physicians to use new generation antifungal drugs or drug combinations. We report a case of invasive Fusarium infection involving the nasopharynx, skin and lungs, following haploidentical hematopoietic stem cell transplantation in an 8-year old patient with recurrent leukemia. The patient was treated with combination antifungal treatment of amphotericin B and voriconazole, as well as supportive care, with the improvement of his symptoms and home discharge. We reviewed the history of combination antifungal therapy. Combination antifungal treatment has been used since 1979, especially in immunocompromised patients. Although randomized controlled trials are lacking, reports favoring combination, especially for invasive mold infections, are increasingly published.


Subject(s)
Antifungal Agents/therapeutic use , Fusariosis/drug therapy , Hematopoietic Stem Cell Transplantation/methods , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Child , Dermatomycoses/drug therapy , Dermatomycoses/etiology , Dermatomycoses/microbiology , Drug Therapy, Combination , Fusariosis/etiology , Humans , Immunocompromised Host , Leukemia/therapy , Lung Diseases, Fungal/drug therapy , Lung Diseases, Fungal/etiology , Lung Diseases, Fungal/microbiology , Male , Nasopharyngeal Diseases/drug therapy , Nasopharyngeal Diseases/etiology , Nasopharyngeal Diseases/microbiology , Pyrimidines/administration & dosage , Pyrimidines/therapeutic use , Treatment Outcome , Triazoles/administration & dosage , Triazoles/therapeutic use , Voriconazole
17.
Medicine (Baltimore) ; 101(45): e31594, 2022 Nov 11.
Article in English | MEDLINE | ID: mdl-36397380

ABSTRACT

BACKGROUND: Fusarium is a conditional pathogen that can cause invasive infection in patients with hematological diseases under immune function. METHODS: A case of recurrent and refractory Philadelphia chromosome-positive acute lymphoblastic leukemia was treated with allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor-modified T cells treatment. RESULTS: During transplantation, disseminated Fusarium infection occurred, involving the skin, liver, spleen and central nervous system, and the patient eventually died. CONCLUSIONS: Early identification of Fusarium infection based on the characteristic rash and timely antifungal treatment can improve the cure rate.


Subject(s)
Fusariosis , Fusarium , Hematopoietic Stem Cell Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Humans , Fusariosis/drug therapy , Fusariosis/etiology , Transplantation, Homologous/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
19.
BMC Ophthalmol ; 11: 30, 2011 Nov 02.
Article in English | MEDLINE | ID: mdl-22044440

ABSTRACT

BACKGROUND: To report a case of disseminated fusariosis with endogenous endophthalmitis in a patient with acute lymphoblastic leukemia. Transfusion-associated immune modulation secondary to platelet transfusion could play an important role in the pathophysiology of this case. CASE PRESENTATION: A 9 year-old male with acute lymphoblastic leukemia complicated by pancytopenia and disseminated Intravascular coagulation was given platelet transfusion. He developed disseminated fusariosis and was referred to the ophthalmology team for right endogenous endophthalmitis. The infection was controlled with aggressive systemic and intravitreal antifungals. CONCLUSION: Patients with acute lymphoblastic leukemia are predisposed to endogenous fungal endophthalmitis. Transfusion-associated immune modulation may further increase host susceptibility to such opportunistic infections.


Subject(s)
Endophthalmitis/etiology , Eye Infections, Fungal/etiology , Fusariosis/etiology , Platelet Transfusion/adverse effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Child , Humans , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
20.
Cornea ; 40(11): 1453-1461, 2021 Nov 01.
Article in English | MEDLINE | ID: mdl-34633358

ABSTRACT

PURPOSE: Fungal keratitis (FK) is a serious ophthalmic disease with a potentially devastating outcome that seems to be increasing in recent years. The use of contact lenses (CLs) was evaluated as a risk factor for FK to determine possible differences in course and outcome. METHODS: Data from 173 cases reported in the German FK registry until August 2019 were evaluated regarding CL behavior, other ophthalmological and general risk factors, age, sex, identified pathogens, conservative and surgical therapy, visual acuity, and findings at admission and follow-up. RESULTS: One hundred seventy-four eyes from 173 patients between 2000 and 2019 were included [64.4% women, median age 54 (39; 72) years]; 49.7% wore CL, of which 81.3% were soft CL, and 50.3% had no history of contact lens use (NCL). CL users were significantly more often women and otherwise healthy (CL: 80.2% vs. NCL: 48.9%; P < 0.0001). The spectrum of pathogens among CL users showed a significantly higher proportion of infections with filamentous pathogens, in particular Fusarium sp. (total filament: CL 69.8% vs. NCL 27.3%; P = 0.0001; Fusarium sp.: CL 50.0% vs. NCL 14.8%; P < 0.0001). Overall, 54.6% required keratoplasty and 8.6% enucleation. CONCLUSIONS: CLS are the most important risk factor for FK in Germany. With CLs, typically, the infection is caused by molds, and patients are comparably younger and otherwise healthy. Often, extensive surgery is needed. To evaluate changes in the pathogen and resistance spectrum and to further monitor possible CL-related risk factors, a consistent collection of data remains paramount.


Subject(s)
Contact Lenses/adverse effects , Cornea/diagnostic imaging , Eye Infections, Fungal/etiology , Fusariosis/etiology , Fusarium/isolation & purification , Keratitis/etiology , Registries , Adult , Aged , Contact Lenses/microbiology , Cornea/microbiology , Eye Infections, Fungal/epidemiology , Eye Infections, Fungal/microbiology , Female , Fusariosis/diagnosis , Fusariosis/microbiology , Germany/epidemiology , Humans , Incidence , Keratitis/epidemiology , Keratitis/microbiology , Male , Middle Aged , Prospective Studies , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL